제2형 신경섬유종증 환자에서 bevacizumab 사용 중단 후 발생한 반동성 종양 증식이 의심되는 1예

A case of suspected rebound tumor progression after withdrawal of bevacizumab in patient with neurofibromatosis type 2

Neurofibromatosis type 2 (NF2) is a rare hereditary disease characterized as bilateral vestibular schwannoma and other tumors of the brain or spinal nerve. There is no effective medical treatment for progressive NF2 other than surgical resection or radiation therapy. Recently, the anti-vascular endothelial growth factor (VEGF), bevacizumab, has been used for progressive vestibular schwannoma in NF2 patients to reduce tumor size and preserve hearing. However, there are some studies of rebound progression after withdrawal of bevacizumab. We report a case of a 24-year-old man with NF2 who was treated with bevacizumab. Bevacizumab was discontinued after 16 months of use. The patient was expired after six months.